

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
08 October 2020 (08.10.2020)



(10) International Publication Number
WO 2020/201991 A1

(51) International Patent Classification:

C07D 401/14 (2006.01) C07D 519/00 (2006.01)
C07D 403/04 (2006.01) A61K 31/53 (2006.01)
C07D 451/04 (2006.01) A61P 35/00 (2006.01)
C07D 471/10 (2006.01) C07D 513/10 (2006.01)
C07D 491/107 (2006.01)

(21) International Application Number:

PCT/IB2020/053019

(22) International Filing Date:

30 March 2020 (30.03.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/828,356 02 April 2019 (02.04.2019) US
62/992,558 20 March 2020 (20.03.2020) US

(71) Applicant: **ARRAY BIOPHARMA INC.** [US/US]; 3200 Walnut Street, Boulder, Colorado 80301 (US).

(72) Inventors: **BLAKE, James F.**; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **BOYS, Mark Laurence**; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **CHICARELLI, Mark Joseph**; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **COOK, Adam W.**; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **ELSAYED, Mohamed S. A.**; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **FELL, Jay Bradford**; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **FISCHER, John P.**; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **HINKLIN, Ronald Jay**; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **JIANG, Yutong**; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **MCNULTY, Oren T.**; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **MEJIA, Macedonio J.**; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **RODRIGUEZ, Martha E.**; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US).

WONG, Christina E.; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US).

(74) Agent: **ZIELINSKI, Bryan C.**; Pfizer Inc., 235 East 42nd Street, MS 235/9/S20, New York, New York 10017 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: PROTEIN TYROSINE PHOSPHATASE INHIBITORS



I

(57) Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for *in vitro*, *in situ*, and *in vivo* diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.



WO 2020/201991 A1